{"product_id":"sarepta-bcg-matrix","title":"Sarepta Therapeutics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSarepta’s BCG Matrix snapshot shows which therapies are sprinting ahead and which need a rethink — a quick, honest look at Stars, Cash Cows, Dogs, and Question Marks in a high-stakes biotech market. This preview teases the patterns; the full BCG Matrix gives quadrant-by-quadrant evidence, strategic recommendations, and ready-to-use Word and Excel files. Purchase the complete report to cut through the noise and make confident, capital-allocation decisions now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eELEVIDYS (DMD gene therapy)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eELEVIDYS, the first FDA‑approved gene therapy for Duchenne muscular dystrophy (approval 2021), is Sarepta’s lead asset in a gene therapy market growing at double‑digit annual rates; DMD affects roughly 1 in 3,500–5,000 male births, creating a focused patient pool. The program drives prescriber interest and payer dialogue but requires continued investment in manufacturing scale, label expansion, and real‑world evidence generation. Hold the share: with scaled production and broader indications, ELEVIDYS can pivot into a substantial cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDMD leadership position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommanding presence across DMD centers and KOL networks gives Sarepta a de facto leadership in a market with an estimated 9,000–12,000 diagnosed US patients (2024) and ~7–9% CAGR growth; brand gravity accelerates trial recruitment, guides guideline influence, and shortens adoption cycles. Defending the moat requires sustained medical education, field strength, and lifecycle programs to compound growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV manufacturing \u0026amp; platform know‑how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHard-won AAV process, QC and supply know-how positions Sarepta as a category leader in 2024, differentiating its franchise as demand for gene therapies surges. Ongoing capacity build-out is cash-intensive today but directly underpins clinical and commercial velocity. Rising utilization will markedly improve unit economics and margins. The AAV platform is a strategic asset that anchors long-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer access momentum in rare disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-cost, one-time rare-disease therapies require heavy payer-access work but create a flywheel: each positive coverage decision reduces friction for subsequent approvals; Zolgensma launched at $2.125M illustrates the million-dollar pricing backdrop. Outcomes-data generation remains resource-intensive, driving near-term spend for long-term leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess intensity: high\u003c\/li\u003e\n\u003cli\u003ePricing context: $2.125M benchmark\u003c\/li\u003e\n\u003cli\u003eStrategy: near-term spend, long-term coverage gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data flywheel (DMD)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExpanding datasets, patient registries and real-world evidence in DMD (prevalence ~1 in 3,500–5,000 male births) reinforce Sarepta’s leadership by accelerating label expansions and payer confidence. Robust data drives prescriber comfort and supports premium pricing (exon-skipping products ~300,000 USD\/year; single-dose gene therapies exceed 2 million USD), but curation is costly. The compounding, proprietary data moat is hard to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDatasets → label \u0026amp; payer leverage\u003c\/li\u003e\n\u003cli\u003eRWE → prescriber adoption\u003c\/li\u003e\n\u003cli\u003eHigh maintenance costs\u003c\/li\u003e\n\u003cli\u003eDurable competitive moat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy leader: \u003cstrong\u003e9,000–12,000\u003c\/strong\u003e US DMD market, single‑dose pricing ~\u003cstrong\u003e$2.125M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eELEVIDYS (FDA 2021) anchors Sarepta’s Star: leadership in a 9,000–12,000 US DMD patient market (2024) with double‑digit gene‑therapy growth; high upfront R\u0026amp;D and manufacturing spend compress near‑term margins but scale drives margin expansion and pricing power (single‑dose benchmarks \u0026gt;$2M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnosed US DMD\u003c\/td\u003e\n\u003ctd\u003e9,000–12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS approval\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene therapy price benchmark\u003c\/td\u003e\n\u003ctd\u003e$2.125M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix of Sarepta’s portfolio: identifies Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG view placing Sarepta Therapeutics units in quadrants to ease strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExondys 51 (eteplirsen)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExondys 51 (eteplirsen), approved in 2016 as the first exon‑51 skipping therapy for DMD, retains entrenched use in the ~13% of DMD patients amenable to exon 51 skipping. Mature demand and a stable prescriber base keep incremental promo needs low; with an approximate list price near $300,000\/year, it delivers solid margins and reliable cash to fund next‑wave programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyondys 53 (golodirsen)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVyondys 53 (golodirsen), approved in 2019, serves the roughly 8% of Duchenne patients amenable to exon 53 skipping. By 2024 it showed predictable volumes and reimbursement patterns across major markets. Growth is limited, but manufacturing and distribution remain efficient and low-cost to support. It continues as a steady contributor to Sarepta’s operating cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmondys 45 (casimersen)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmondys 45 (casimersen) was FDA‑approved on February 25, 2021 for DMD amenable to exon 45 skipping, a mutation present in roughly 8% of DMD patients. As a later RNA‑entry therapy it targets a consistent patient pool; growth is modest but profitability benefits from shared commercial infrastructure and field synergies. Its smaller but steady revenues help underwrite Sarepta’s high‑risk R\u0026amp;D pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. DMD commercial infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eU.S. DMD commercial infrastructure underpins Sarepta as a cash cow: seasoned market access, robust patient services and a national distribution network now optimized for scale with lower incremental costs, keeping churn low and adherence high; serves an estimated 15,000–20,000 US DMD patients (2024) and quietly throws off dependable cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket access: national payer relationships\u003c\/li\u003e\n\u003cli\u003ePatient services: care coordination, adherence support\u003c\/li\u003e\n\u003cli\u003eDistribution: centralized logistics, lower incremental cost\u003c\/li\u003e\n\u003cli\u003eScale impact: steady recurring revenue, low churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle \u0026amp; label maintenance revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLifecycle and label-maintenance revenues from Sarepta's approved exon-skipping and gene-targeted therapies deliver steady, incremental indications and age-range expansions that lift persistence with minimal new launch spend, creating a high-margin tail as DMD markets mature and providing ballast in volatile biotech cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncremental indications: label expansions\u003c\/li\u003e\n\u003cli\u003eAge-range use: broader pediatric\/adolescent uptake\u003c\/li\u003e\n\u003cli\u003ePersistence lift: longer treatment duration\u003c\/li\u003e\n\u003cli\u003eLow incremental spend vs early launches\u003c\/li\u003e\n\u003cli\u003eHigh-margin tail, stabilizes revenue volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExon-targeted DMD therapies cover ~29% of patients; US pool 15,000–20,000; price ~\u003cstrong\u003e300,000\u003c\/strong\u003e\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExondys 51 (2016), Vyondys 53 (2019) and Amondys 45 (2021) serve ~13%, ~8% and ~8% of DMD patients respectively, with Exondys list price ~300,000\/year. US DMD pool est. 15,000–20,000 (2024), mature access and patient services keep promo costs low and margins high, providing dependable cash to fund R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTherapy\u003c\/th\u003e\n\u003cth\u003eApproval\u003c\/th\u003e\n\u003cth\u003ePatient %\u003c\/th\u003e\n\u003cth\u003eList price (yr)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExondys 51\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003ctd\u003e~13%\u003c\/td\u003e\n\u003ctd\u003e~300,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyondys 53\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmondys 45\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eSarepta Therapeutics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing is the final Sarepta Therapeutics BCG Matrix you’ll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report tailored to Sarepta’s portfolio. It’s crafted for strategic clarity and immediate use in presentations or planning. Buy once, download instantly, edit or print as needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674647347577,"sku":"sarepta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/sarepta-bcg-matrix.png?v=1755792928","url":"https:\/\/portersfiveforce.com\/products\/sarepta-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}